Abstract
Little has been published about long-acting opioid (LAO) versus short-acting opioid (SAO) use for pain in sickle cell disease (SCD), which is often chronic. We report on home LAO versus SAO use among a cohort of SCD adults (n=219) who completed daily pain diaries for up to 6 months and had at least one home pain day. We measured daily use of any opioids, LAO, SAO, other analgesics, adjuvants, and pain intensity (0-9 Likert scale), as well as pain frequency (0-100% of days), hydroxyurea (HU) use and avascular necrosis (AVN).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
